Narcolepsy Type 1 Clinical Trial
— NARCOSPORTOfficial title:
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
Verified date | January 2024 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy (emotionally triggered episodes of muscle atonia). The disease is associated with numerous comorbidities such as obesity, metabolic disorders, anxiety-depressive disorders, and attentional disorders, all of which have a strong impact on quality of life.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 24, 2023 |
Est. primary completion date | November 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Diagnosis of Narcolepsy type 1 according to International Classification of Sleep Disorders, 3rd edition (ICSD 3-2014) criteria - Patients aged 18 to 65 years - Patients beneficiaries of social security - Signed consent to participate in the study - Access to a video conferencing device (smartphone, tablet or computer) Exclusion Criteria: - - Patients with a high level of physical activity on the Ricci and Gagnon Questionnaire (score >35) and/or regular physical activity in clubs - Treatments not stabilized for less than 3 months - Cognitive disorders incompatible with the understanding and implementation of the program - Medical contraindication to exercise training - Patient working night shifts - Unstable somatic or psychiatric pathology - Severe untreated obstructive sleep apnea syndrome (apnea/hypopnea index >30/h) - Pregnancy in progress or breastfeeding - Persons deprived of liberty by a judicial or administrative decision, - Persons admitted to a health or social institution for purposes other than research - Persons of full age who are subject to a legal protection measure or who are unable to express their consent |
Country | Name | City | State |
---|---|---|---|
France | Service de médecine du sommeil et des maladies respiratoires | Lyon |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Narcolepsy Severity Scale (NSS) Score after training period. | The Narcolepsy Severity Scale is a validated scale exploring the different symptoms of NT1 | before and after 6 weeks of physical activity program (training period) | |
Secondary | Narcolepsy Severity Scale (NSS) Score | The Narcolepsy Severity Scale is a validated scale exploring the different symptoms of NT1 | At 6 months | |
Secondary | Compliance with the training program. | It will be expressed as the percentage of sessions completed | weekly during the training period (up to 6 weeks) | |
Secondary | Hospital and Anxiety Depression Scale score | At inclusion, at the end of the training program (6 weeks) and at 6 months | ||
Secondary | Frequency of cataplexy | Items 8and 9 of the NSS are used to assess frequency of cataplexy | every week during de training period (6 weeks) | |
Secondary | Bron/Lyon Attention Stability Test (BLAST) score | Parameters will be measured at inclusion, at the end of the training program (6 weeks) | ||
Secondary | body mass index | Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months* | ||
Secondary | Maximal Oxygen consumption (VO2 max) | Parameters will be measured at inclusion, at the end of the training program (6 weeks) | ||
Secondary | Fasting blood sugar | Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months* | ||
Secondary | Lipid profile | Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months* | ||
Secondary | patient satisfaction score | Parameters will be measured at inclusion, at the end of the training program (6 weeks) | ||
Secondary | sleep efficiency | Sleep efficiency is defined as the ratio between total sleeping time and time spent in bed | Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months* | |
Secondary | Euroquol 5 dimensions questionnaire score | At inclusion, at the end of the training program (6 weeks) and at 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05983731 -
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
|
||
Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
Completed |
NCT05375890 -
Clinical and Neurophysiological Characteristics of Narcolepsy
|
||
Not yet recruiting |
NCT06292598 -
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
|
||
Recruiting |
NCT06358950 -
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
|
Phase 2 | |
Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
Not yet recruiting |
NCT06383806 -
Decreasing Nightmares in Adults With Narcolepsy
|
N/A | |
Not yet recruiting |
NCT05914194 -
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
|
Phase 3 | |
Completed |
NCT05687903 -
A Study of TAK-861 in Participants With Narcolepsy Type 1
|
Phase 2 | |
Recruiting |
NCT05967832 -
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy
|
N/A | |
Completed |
NCT05709873 -
Narcolepsy Nightmare Study
|
N/A | |
Recruiting |
NCT04483310 -
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
|
N/A | |
Completed |
NCT04445129 -
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
|
||
Completed |
NCT05314556 -
Group Psychotherapy in Narcolepsy Type 1
|
N/A | |
Recruiting |
NCT05816382 -
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
|
Phase 2/Phase 3 | |
Recruiting |
NCT06336057 -
Mentalizating in Adults Suffering From Narcolepsy Type 1.
|
||
Recruiting |
NCT06251063 -
Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
|
N/A | |
Completed |
NCT06241911 -
Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
|
N/A |